Surprex
Antineoplastic, tyrosine kinase inhibitor. Indicated as an oral treatment for patients with advanced renal cancer, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
Therapeutic Area
Oncology
Active Ingredient
Sunitinib
Line
Oncology
Dosage forms
12.5 mg x 28 capsules
25 mg x 28 capsules
50 mg x 28 capsules
